kabutan

PRISM BioLab Co.,LTD(206A) Summary

206A
TSE Growth
PRISM BioLab Co.,LTD
184
JPY
+10
(+5.75%)
Jan 29, 3:30 pm JST
1.20
USD
Jan 29, 1:30 am EST
Result
PTS
outside of trading hours
186
Jan 29, 7:16 pm JST
Summary Chart Historical News Financial Result
PER
PBR
2.52
Yield
ー%
Margin Trading Ratio
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
179 JPY 1.16 USD
Previous Close Jan 28
174 JPY 1.14 USD
High Jan 29, 1:03 pm
189 JPY 1.23 USD
Low Jan 29, 9:03 am
174 JPY 1.13 USD
Volume
406,400
Trading Value
0.07B JPY 0.48M USD
VWAP
181.63 JPY 1.19 USD
Minimum Trading Value
18,400 JPY 120 USD
Market Cap
6.80B JPY 0.04B USD
Number of Trades
358
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Mid
1-Year Average
392
1-Year High Dec 2, 2025
10,028
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 0 2,141,900
Jan 16, 2026 0 2,126,600
Jan 9, 2026 0 2,171,900
Dec 26, 2025 0 2,379,100
Dec 19, 2025 0 2,604,500
Company Profile
PRISM BioLab Co., LTD engages in the research and development of new drugs using its proprietary drug discovery platform (PepMetics technology).
Sector
Pharmaceuticals
PRISM BioLab is a research and development-oriented venture company focusing on drug discovery utilizing its proprietary PepMetics technology platform. The company is dedicated to creating small molecule drugs targeting intracellular protein-protein interactions (PPIs). By leveraging its unique compound library and synthesis techniques, PRISM BioLab has overcome the challenges associated with traditional approaches, which often resulted in large molecular weight compounds with potential side effects. The company's innovative small molecule compounds have successfully cleared these hurdles, enabling the development of PPI inhibitors. PRISM BioLab has multiple pipelines, including Wnt inhibitors and translation control agents, and pursues both in-house development and collaborative projects with pharmaceutical companies. By pioneering the new drug discovery field of intracellular PPIs, PRISM BioLab aims to create innovative pharmaceuticals for diseases that currently lack effective treatments.